TY - JOUR
T1 - Mental disorders and termination of education in high-income and low and middle-income countries
T2 - Epidemiological study
AU - Lee, S.
AU - Tsang, A.
AU - Breslau, J.
AU - Aguilar-Gaxiola, S.
AU - Angermeyer, M.
AU - Borges, G.
AU - Bromet, E.
AU - Bruffaerts, R.
AU - De Girolamo, G.
AU - Fayyad, J.
AU - Gureje, O.
AU - Haro, J. M.
AU - Kawakami, N.
AU - Levinson, D.
AU - Browne, M. A Oakley
AU - Ormel, J.
AU - Posada-Villa, J.
AU - Williams, D. R.
AU - Kessler, R. C.
PY - 2009
Y1 - 2009
N2 - Background Studies of the impact of mental disorders on educational (OR=1.4) and impulse control disorders (OR=2.2) were attainment are rare in both high-income and low- and associated with early termination of secondary education. In middle-income (LAMI) countries. LAMI countries, impulse control disorders (OR=1.3) and substance use disorders (OR=1.5) were associated with early Aims . termination of secondary education. To examine the association between early-onset mental disorder and subsequent termination of education. Conclusions Onset of mental disorder and subsequent non-completion of Method education are consistently associated in both high-income Sixteen countries taking part in the World Health and LAMI countries. Organization World Mental Health Survey Initiative were surveyed with the Composite International Diagnostic Declaration of interest Interview (n=41 688). Survival models were used to estimate R.C.K. has been a consultant for GlaxoSmithKline, Kaiser associations between DSM-IV mental disorders and Permanente, Pfizer Inc, Sanofi-Aventis, Shire Pharmaceuticals subsequent non-attainment of educational milestones. and Wyeth-Ayerst; has served on advisory boards for Eli Lilly & Company and Wyeth-Ayerst; and has had research support Results for his epidemiological studies from Bristol-Myers Squibb, Eli In high-income countries, prior substance use disorders were Lilly & Company, GlaxoSmithKline, Johnson & Johnson associated with non-completion at all stages of education Pharmaceuticals, Ortho-McNeil Pharmaceutical mc, Pfizer Inc (OR 1.4-15.2). Anxiety disorders (OR=1.3), mood disorders and Sanofi-Aventis.
AB - Background Studies of the impact of mental disorders on educational (OR=1.4) and impulse control disorders (OR=2.2) were attainment are rare in both high-income and low- and associated with early termination of secondary education. In middle-income (LAMI) countries. LAMI countries, impulse control disorders (OR=1.3) and substance use disorders (OR=1.5) were associated with early Aims . termination of secondary education. To examine the association between early-onset mental disorder and subsequent termination of education. Conclusions Onset of mental disorder and subsequent non-completion of Method education are consistently associated in both high-income Sixteen countries taking part in the World Health and LAMI countries. Organization World Mental Health Survey Initiative were surveyed with the Composite International Diagnostic Declaration of interest Interview (n=41 688). Survival models were used to estimate R.C.K. has been a consultant for GlaxoSmithKline, Kaiser associations between DSM-IV mental disorders and Permanente, Pfizer Inc, Sanofi-Aventis, Shire Pharmaceuticals subsequent non-attainment of educational milestones. and Wyeth-Ayerst; has served on advisory boards for Eli Lilly & Company and Wyeth-Ayerst; and has had research support Results for his epidemiological studies from Bristol-Myers Squibb, Eli In high-income countries, prior substance use disorders were Lilly & Company, GlaxoSmithKline, Johnson & Johnson associated with non-completion at all stages of education Pharmaceuticals, Ortho-McNeil Pharmaceutical mc, Pfizer Inc (OR 1.4-15.2). Anxiety disorders (OR=1.3), mood disorders and Sanofi-Aventis.
UR - http://www.scopus.com/inward/record.url?scp=67649347934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649347934&partnerID=8YFLogxK
U2 - 10.1192/bjp.bp.108.054841
DO - 10.1192/bjp.bp.108.054841
M3 - Article
C2 - 19407270
AN - SCOPUS:67649347934
VL - 194
SP - 411
EP - 417
JO - British Journal of Psychiatry
JF - British Journal of Psychiatry
SN - 0007-1250
IS - 5
ER -